Back then, the Tsuji led research still didn't find a way to multiply epithelial stems cells, a very necessary part for their cloned/bioengineered follicle approach to work, as stated by one of their senior researchers, Koh-ei Toyoshima:
Clearly, their biggest problem back then was related to the amplification of the epithelial stem cells. And we never had a clear hard confirmation that they ever solved that problem.
Now the weird part: the expansion/multiplication of epithelial stems cells is a problem that was already solved by another scientists back in 2014, as demonstrated in this study: Generation of folliculogenic human epithelial stem cells from induced pluripotent stem cells.
From an article related to that discovery:
So, yea, I wonder why the Tsuji team couldn't solve a problem that was already solved? Maybe they didn't want to use the same approach used by Dr. Xu for some reason? Dr. Xu used iPSC by the way, the same cells Dr. Terskikh from Stemson is using for the generation of dermal papilla stem cells (and epithelial cells too I presume even though he never addressed that part).
Mr. Toyoshima: For applications of our technology, both mesenchymal stem cells and epithelial stem cells, which are applicable to human clinical applications, are needed. With respect to the development of the technology to cultivate mesenchymal stem cells, that is papilla cells, being applicable to human clinical trials, we are already in progress now for development. On the other hand, as for the technology to cultivate epithelial stem cells of follicles, it still remains a significant challenge globally. We are currently in the middle of research and development for this. Based on our recent research results, we finally have some prospects and expect this issue to be resolved in the near future.
Keiko: That is a huge step toward the clinical application, isn’t it?
Mr. Toyoshima: Yes, in terms of transitioning from basic research to clinical application, we are finally coming out of the basic research phase toward the clinical application phase.
Keiko: Thank you. Are there any other roadblocks preventing forward progress on this project?
Mr. Toyoshima: Well… at this point, the challenge which I’ve just mentioned is the biggest challenge we face. There are other challenges, but they are rather related to engineering, so in terms of a roadblock for the clinical applications, we believe our issue has been almost solved.
Clearly, their biggest problem back then was related to the amplification of the epithelial stem cells. And we never had a clear hard confirmation that they ever solved that problem.
Now the weird part: the expansion/multiplication of epithelial stems cells is a problem that was already solved by another scientists back in 2014, as demonstrated in this study: Generation of folliculogenic human epithelial stem cells from induced pluripotent stem cells.
From an article related to that discovery:
Dr. Xu says that this “is the first time anyone has made scalable amounts of epithelial stem cells that are capable of generating the epithelial component of hair follicles,” adding that the cells could aid in wound healing, cosmetics and hair regeneration.
So, yea, I wonder why the Tsuji team couldn't solve a problem that was already solved? Maybe they didn't want to use the same approach used by Dr. Xu for some reason? Dr. Xu used iPSC by the way, the same cells Dr. Terskikh from Stemson is using for the generation of dermal papilla stem cells (and epithelial cells too I presume even though he never addressed that part).
Last edited: